Advancing PROTAC Characterization: Structural Insights through Adducts and Multimodal Tandem-MS Strategies.
Mohammed RahmanBryan MarzulloStephen W HolmanMark P BarrowAndrew D RayPeter B O'ConnorPublished in: Journal of the American Society for Mass Spectrometry (2024)
Proteolysis targeting chimeras (PROTACs) are specialized molecules that bind to a target protein and a ubiquitin ligase to facilitate protein degradation. Despite their significance, native PROTACs have not undergone tandem mass spectrometry (MS) analysis. To address this gap, we conducted a pioneering investigation on the fragmentation patterns of two PROTACs in development, dBET1 and VZ185. Employing diverse cations (sodium, lithium, and silver) and multiple tandem-MS techniques, we enhanced their structural characterization. Notably, lithium cations facilitated comprehensive positive-mode coverage for dBET1, while negative polarity mode offered richer insights. Employing de novo structure determination on 2DMS data from degradation studies yielded crucial insights. In the case of VZ185, various charge states were observed, with [M + 2H] 2+ revealing fewer moieties than [M + H] + due to charge-related factors. Augmenting structural details through silver adducts suggested both charge-directed and charge-remote fragmentation. This comprehensive investigation identifies frequently dissociated bonds across multiple fragmentation techniques, pinpointing optimal approaches for elucidating PROTAC structures. The findings contribute to advancing our understanding of PROTACs, pivotal for their continued development as promising therapeutic agents.
Keyphrases
- mass spectrometry
- tandem mass spectrometry
- liquid chromatography
- multiple sclerosis
- ms ms
- solar cells
- high performance liquid chromatography
- ultra high performance liquid chromatography
- solid phase extraction
- gas chromatography
- gold nanoparticles
- simultaneous determination
- ionic liquid
- protein protein
- amino acid
- silver nanoparticles
- palliative care
- genome wide
- electronic health record
- binding protein
- cancer therapy
- small molecule
- gene expression
- case control